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ABSTRACT 
 
As obesity continues to grow and medical costs in the United States are estimated at $147 
billion annually, novel ways to prevent and treat obesity are needed. One approach is to promote 
thermogenesis to improve energy balance by increasing the activities of thermogenic brown and 
beige adipocytes.  
Naringenin, a citrus flavanone, has been shown to act as anti-inflammatory and lipid 
lowering agent as well as activate PPARgamma. However, it is unclear whether it can activate 
thermogenic activity in white adipocytes, i.e., promote formation of beige adipocytes. 
Indomethacin (INDO) is an FDA approved drug used to treat pain related to inflammation by 
inhibiting cyclooxygenase (COX). It has been demonstrated that INDO is a PPARgamma agonist 
and is protective against weight gain in mice fed a high fat and high sucrose diet. Whether INDO 
independently induces brown adipocyte differentiation has not been studied.  
In this thesis, I investigated the effect of naringenin combined with isoproterenol, a beta-
adrenergic receptor agonist on thermogenic activation of a common white adipocyte cell line, 
3T3-L1. In addition, I investigated whether INDO induces brown adipocyte differentiation. 3T3-
L1 cells were differentiated into mature adipocytes with a standard differentiation cocktail in the 
presence of naringenin and then stimulated with isoproterenol. While naringenin had little effect 
at the basal level, it significantly increased mRNA and protein expression of UCP-1 and PGC-
1alpha, browning marker genes. Moreover, naringenin increased mitochondrial DNA, which is 
indicative of increased mitochondrial biogenesis.  The results suggest that in addition to 
increased UCP-1 expression, naringenin can promote up regulation of PGC-1alpha, leading to 
increased mitochondrial biogenesis in thermogenic activation of 3T3-L1. 
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 To study the effects of INDO on brown adipocyte differentiation I differentiated brown 
preadipocytes in the presence of increasing doses of INDO using a modified differentiation 
protocol. INDO dose-dependently increased lipid accumulation and mRNA expression of brown 
specific marker genes PGC-1alpha, UCP-1 and PRDM16. Protein expression of PGC-1alpha and 
UCP-1 was confirmed by western analysis. Consistently, INDO dose-dependently increased 
mitochondrial biogenesis. Mechanistically, INDO increased PPAR responsive promoter 
activities. These results suggest that INDO may promote brown adipogenesis through activation 
of PPARgamma.  
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CHAPTER I 
INTRODUCTION 
 
A major health issue in the United States (US) is obesity. One-third of US adults, totaling 
78.6 million, are obese.1 Children are also experiencing this disease with childhood obesity 
affecting 17% of individuals 2-19 years of age.2 The estimated cost of adult obesity is 147 billion 
dollars annually. An obese individual costs an additional $1,429 in healthcare each year. This is 
due to the complications of obesity that include; type 2 diabetes, cardiovascular disease, 
hypertension, dyslipidemia and certain cancers. Many factors contribute to obesity such as 
environment, genetics, diet, behaviors, socioeconomic status and particular illnesses. All of these 
factors contribute to positive energy balance, that creates excess adiposity.1 
Adipose tissue includes white, brown and beige phenotypes. White adipose tissue 
(WAT), the primary site of energy storage within the body, is composed of mostly triglycerides, 
up to 85%,3and has been an evolving topic of interest for research due to its endocrine 
contributions and its role in systemic inflammation.  
The second type of adipose tissue is brown adipose tissue (BAT), whose main function is 
non-shivering thermogenesis in addition to lipid storage. The non-shivering thermogenic 
function of BAT is due primarily to the expression of the unique protein uncoupling protein 1 
(UCP-1).3 It was originally assumed that BAT was exclusively present in neonates. The recent 
discovery of BAT in human adults along with its ability to increase non-shivering thermogenesis 
has made BAT a novel target for obesity treatment and prevention.4-6  
A third adipose cell phenotype is beige, which is thought to be derived from WAT 
adipose depots and can be induced to express UCP-1 for increased thermogenic activity. Much 
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interest has been sparked in this area of research as it may lead to novel strategies to combat 
obesity and its related diseases.7  
Peroxisome proliferator activated receptor gamma coactivator- 1 alpha (PGC-1α) is a 
transcription factor coactivator that is known for its function in regulating mitochondria 
biogenesis and oxidative metabolism.8 PGC-1α acts to coactivate peroxisome proliferator 
activated receptor gamma (PPARγ) that binds at the PPRE site of various adipogenic genes to 
promote transcription, including those related to differentiation and that of the UCP-1 promoter. 
PGC-1α is important in cellular metabolism and is regulated by other important signals such as 
increased cAMP,9 p38MAPK phosphorylation,10 and SIRT1 deacetylation.11 Due to its role in 
metabolism, it may be beneficial target to increase thermogenesis in adipocytes. 
Several compounds including nutrients and pharmaceuticals are being investigated for 
their potential to influence cellular targets for obesity treatment and prevention. Polyphenols 
have become more popular in research as they have been reported to exert a variety of beneficial 
effects on metabolism and health.12 Naringenin a member of the flavanone class of polyphenols 
has been shown to improve lipid metabolism and adiposity in animal models.13 Furthermore, it 
has been shown to be a PPARγ agonist in hepatic cells.14 However, it is not clear whether 
naringenin can induce thermogenic activation in white adipocytes or what role PGC-1α 
In addition to using nutrient based strategies to target thermogenesis for obesity, 
pharmaceutical agents are also studied. Indomethacin is a non-selective cyclooxygenase (COX) 
inhibitor used in the treatment of pain and inflammation.15 It has been shown to promote 
adipogenesis and is protective against high fat/high sucrose diet induced obesity in mice.16  
However, the mechanism that exerts its effects on brown adipocytes is not clear. Additionally it 
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is unknown whether INDO can induce differentiation of brown adipocytes independent of other 
inducers in a typical differentiation cocktail17 (i.e. dexamethasone and IBMX).  
Both naringenin and INDO have been shown to be PPARγ agonists. Rosiglitazone, a 
known PPARγ agonist and browning agent, has been shown to promote thermogenic activation 
in 3T3-L1 cells. PPARγ increases differentiation and this process in brown adipocytes may be 
applied to increased BAT mass in vivo.  We hypothesize that naringenin will promote 
thermogenic activity with a phenotype similar to that of rosiglitazone and that INDO will 
promote brown adipocyte differentiation through PPARγ activation. To fill the knowledge gap, 
the objective of this thesis is to study the effects of both naringenin and INDO on browning and 
brown adipocyte differentiation respectively. Specifically we aim to study the beneficial effects 
of naringenin on PGC-1α in thermogenic activation of 3T3-L1 cells. For INDO, we aim to 
determine if INDO can promote brown adipocyte differentiation of BAT without an induction 
period that includes a corticosteroid using a modified differentiation protocol.  The results 
presented add to our understanding of nutrient and pharmacological regulation of adipose tissue 
and suggest great potential of naringenin and INDO in obesity treatments and prevention. 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Brown Adipose Tissue and Browning: Novel Targets for Intervention  
2.1.1 Function, anatomic location and discovery in adult humans 
Brown adipose tissue (BAT) is a distinct tissue type in the body. It was originally 
accepted that BAT was only present in neonates and there was a rapid regress afterwards.18 
Evidence of BAT in adult humans was found utilizing fluoro-deoxyglucose (FDG) positron 
emission tomography (PET) and X-ray computed tomography (CT). This showed increased 2-
deoxyglucose uptakes during cold stimulation in the supraclavicular and paraspinal regions. The 
presence of BAT was correlated with younger age and lower BMI. 5 A study using the same 
scanning technique and larger sample size found similar results and a higher mass of BAT in 
women.4 These studies confirm the presence of active BAT in humans, and suggest that BAT 
could be a novel target for obesity treatment and prevention.  
BAT is estimated to compose 0.05%- 0.1% of total body weight in an adult human 
compared to 5-10% in mice and 2-5% in human infants.19 The tissue is highly innervated with 
sympathetic nerves, which is the major activator for brown cell thermogenic activity.20 BAT is 
highly vascularized, allowing for access to circulating glucose and lipids as well as distributing 
heat produced by thermogenesis.3  
Recruitment and activation of BAT is due to stimulation of the sympathetic nervous 
system and the release of norepinephrine that activates β-adrenergic receptors expressed on the 
cell surface. This leads to the mobilization of triglycerides from all adipose tissues to increase 
energy availability that can be utilized for thermogenesis.3 Norepinephrine activation of β-
adrenergic receptors has been shown to stimulate thermogenesis in BAT as well as increase cell 
growth and differentiation.3, 21, 22 
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2.1.2 Cellular origins of brown adipose tissue 
Like white adipocytes, brown adipocytes are derived from mesenchymal stem cells. 
Conventional brown cells are from a Myf5+ precursor cell whereas white cells are from Myf5- 
precursor cells. Brown adipose cells arising from the Myf5+ precursor have a closer relation to 
myocytes rather than a white adipocytes.23 It was found in brown preadipocytes, on day 1 of 
differentiation that myogenin, a protein found in skeletal muscle, was transiently expressed then 
declined during the course of adipocyte differentiation; this was not found in white adipocytes.24 
However, both types of adipocytes utilize many common transcriptional factors for 
complete differentiation. Since both types of adipose accumulate lipids during the differentiation 
process it has been shown that 72% of the genes up regulated and 52% that are down regulated 
are similar between the two types.24 In contrast, brown adipocytes up regulated about 100 genes 
that are related to mitochondria.24 Brown cells contain multilocular lipid droplets and more 
mitochondria compared to WAT, that contain unilocular lipids with fewer mitochondria.21  
Another related cell type is called “beige” adipocytes. There are various hypotheses about 
the origin of these cells. It is disputed whether they have unique precursors or if they are from 
transdifferentiation from white adipocytes. Transdifferentiation has not been proven false but 
studies have isolated pre beige cells that have different marker expression than those of white 
preadipocytes.25 Beige cells are localized inside WAT depots but they can be induced to appear 
and function as brown like cells, i.e. with increased mitochondrial content and UCP1 expression. 
This phenomenon is called “browning”.21, 26  
2.1.3 Uncoupling protein 1 (UCP-1) and other key markers of brown adipocytes 
 A major identifying protein for brown adipocytes is uncoupling protein 1 (UCP-1). 
Respiration is uncoupled from ATP synthesis by the UCP-1 protein, which makes the inner 
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mitochondrial membrane more permeable to protons, thus lowering the proton gradient created 
by the electron transport chain, preventing the synthesis of chemical energy (in the form of 
ATP). Five different uncoupling proteins have been identified; however, UCP-1 is specific to 
adipose tissue and its function is the best understood.22  
Wild type and UCP-1 knockout mice were given a β3-andrenergic receptor agonist (CL-
316, 243) to determine the effect of β-adrenergic receptor activation on UCP-1. The wild type 
mice had an increase in oxygen consumption with decreased lipid levels after administration of 
the β-adrenergic agonist. The UCP-1 knockout mice did not experience these changes.27 These 
results point to the importance of UCP-1 in the increased thermogenesis from the stimulation of 
β3-adrenergic receptors in BAT from the SNS.   
 The UCP-1 gene shares a common structure between mice, rats and humans near the 
transcriptional start site as well as a conserved upstream enhancer. UCP-1 promoter contains 
multiple binding sites that allow for the action of PPARs, retinoids, and thyroid hormones. UCP-
1 transcription is mainly activated by norepinephrine released from the nervous system to 
activate β3-andrenergic receptors and its downstream pathways.28, 29 
A transcription factor highly specific to adipocytes is peroxisome proliferator-activated 
receptor gamma (PPARγ). This transcription factor is the key regulator in the differentiation and 
maintenance of both white and brown adipocytes. Low levels of PPARγ are present in 
preadipocytes and are increased to peak at the beginning of differentiation.30 The essential role of 
PPARγ is evidenced by an in vitro study where cells derived from embryonic stem cells were 
used to make a PPARγ knockout. It was found that knock out cells did not differentiate while the 
wild type did.31  
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Rosiglitazone is a known anti-diabetic drug that has been shown to decrease circulating 
lipid levels and act as PPARγ agonists.32 When administered in mice a marked increase in UCP-
1 expression in both lean and obese mice was seen. These results point towards the link between 
the activation of PPARγ and UCP-1 expression. 33 This is due to PPARγ activity binding to the 
PPRE site of the UCP-1 promoter to increase transcription.28  At this site is where PGC-1α 
(peroxisome proliferator activated receptor γ coactivator- 1α) coactivates PPARγ to help drive 
UCP-1 expression.34   
A protein specific to brown adipocytes important for the differentiation of the Myf5+ 
precursor is PR domain-containing protein-16 (PRDM16).35 An experiment with knockdown of 
PRDM16 in primary brown fat cells led to myogenesis and decreased expression of UCP-1, 
PCG-1α and other brown fat identifiers.35, 36 In addition increased PRDM16 expression in 
myoblasts promoted adipogenesis leading to mature brown adipocytes, which may result from an 
increase in PPARγ and UCP-1 expression. PRDM16 has been shown to bind to PCG-1α, 
PPARα37, PPARγ and members of the C/EBP family to enhance their action as DNA-binding 
transcription factors and coactivators.38 Seale and colleagues proposed that a major action of 
PRDM16 was through its interaction with PPARγ35 and it was also shown that PPARγ agonist 
(rosiglitazone) stabilized PRDM16 in white adipocytes to promote browning.39 
2.2 Browning and Beige Adipocytes 
2.2.1 Function, origin, and markers 
 Beige adipocytes are of interest as they can be found in WAT depots but are active in 
thermogenic uncoupling, contributing to energy expenditure. While beige adipocytes have been 
studied and found to have a variety of origins, they are a therapeutic target for obesity and other 
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metabolic diseases.40 In animal studies, the presence of beige cells in classical WAT depots has 
shown to be effective in protecting against diet-induced obesity.  
 Some markers have been tested for the identification of beige adipocytes. However, the 
literature varies in what parameters define a beige adipocyte. Many publications rely on the 
increased expression of brown fat cell markers such as UCP-1, and increased energy expenditure 
along with a white fat origin to define a beige adipocyte. However, beige cells still express UCP-
1 at a lower level than classical brown adipocytes. Studies seeking to determine markers that are 
exclusive to beige cells have identified CD137, Tmem26 and HoxC9.41 A study comparing 
expression of markers in different adipose tissue depots and cell culture of primary adipocytes 
found that Tmem26 and CD137 were reliable markers in tissue but were less specific when 
primary cells were isolated from the tissue and cultured. Cells cultured with rosiglitazone and 
norepinephrine expressed decreased Tmem26 whereas CD137 was increased. This study also 
measured HoxC9 and found that it did not distinguish between beige and white adipocytes; 
however, it did distinguish white and beige cells from brown indicating HoxC9 is able to 
differentiate the depot of origin.42 Another study comparing inguinal WAT as well as primary 
cells from the stromal vascular (SVF) and the adipocyte fraction showed that Tmem26 decreased 
when differentiated into beige cells. In contrast, CD137 increased with differentiation to a beige 
adipocyte in vitro.43 Together these studies indicate that these beige markers may be more 
specific to the precursor beige cells in the tissue rather than fully differentiated cells.  
 Zic1 and Meox-2 are brown adipose markers.24, 36 In beige cells; Petrovic and coauthors 
found that these two markers were not detectable even when PGC-1α and UCP-1 expression was 
increased.44 There is variation in expression of white, brown and beige marker genes between 
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cell lines, animal studies, and human derived cells. Therefore, it is unclear which are the best 
markers to be used that are consistent among cell culture, animals, and humans.41  
 
2.2.2 Common cell models of browning 
 3T3-L1 cells are the most widely used cell line for studying adipose and were utilized in 
392 publications in the last five years comparing to other cell lines that have been used less than 
15 each.45  The 3T3-L1 cell line is derived from mouse embryos of Swiss 3T3 mice at 17 to 19 
days of development. They are preadipocytes that appear like fibroblasts and can be 
differentiated into mature adipocytes.46 They are frequently used due to their low cost and ease 
of use compared to primary cells. However, they can be difficult to transfect and lose the ability 
to differentiate after several passages.47  
3T3-L1 cells have been shown to express higher levels of UCP-1 when treated with 
Rosiglitazone, IBMX, and T3.48 Isoproterenol is a potent, but nonspecific, β-adrenergic receptor 
activator that can induce expression of beige and brown related genes in 3T3-L1 cells. 
Treatments after 6 or 48 hours increased expression of UCP-1, PRDM16 and CD137 and 
increased uncoupling.49 
In contrast, to the cell line, primary cultures from the stromal vascular region (SVF) are 
also used as a model in studies related to adipose tissue cell differentiation process. Unlike other 
cell types, these preadipocytes are more committed and can only be differentiated into 
adipocytes. Primary adipocytes may also have more characteristics related to the depot of origin 
compared to cell lines, providing more information about the differences in cell origin.50 Human 
derived primary cells and cell lines are becoming more available and can be beneficial in 
confirming results found in cell models of animal origin. In addition, human derived primary 
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cells can be used to confirm what is known about cell lineages and differences between cell 
origin related to the fat depot and genetic differences between donors.51, 52  
 
2.2.3 Stimuli and known browning agents 
Several agents to promote “browning” process have been identified. Similar to BAT, 
prolonged cold exposure can promote browning in WAT depots that has been shown in vivo. 
Additionally, many pharmacological inducers of UCP-1 expression in beige cells are β-
adrenergic agonists such as isoproterenol, CGP-12177, or CL-316243.49, 53 54 PPARγ ligands 
such as rosiglitazone, is another well-known inducer of browning. PPARγ agonist activity has 
been shown to increase mitochondrial biogenesis, mitochondrial gene expression, and increase 
UCP-1 expression.44, 55, 56 
 Beyond pharmaceuticals, dietary components, such as polyphenols and lipids have been 
studied in relation to browning. Capsaicin has been shown to promote browning in vitro, and 
increased browning alongside resistance to HFD-induced obesity in rats.57, 58 Resveratrol has 
been shown to increase UCP-1 expression and mitochondrial content in mouse embryonic 
fibroblasts (MEF) but failed to increase UCP-1 in 3T3-L1 adipocytes.59 Additionally, omega-3 
fatty acids have been shown to increase the expression of PGC-1α, Nrf (nuclear respiratory 
factor), and CPT1 (Carnitine palmitoyltransferase 1) with increased beta-oxidation but did not 
increase UCP-1 in WAT in mice.60 In rats fed a high fat diet, thermogenesis increased with the 
addition of omega-3 fatty acids to the lipid composition of the diet.61 
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2.3 Peroxisome Proliferator-Activated Receptor γ  Co-activator-1a (PGC-1α)  
Peroxisome proliferator-activated receptor γ co-activator-1a (PGC-1α) was identified as a 
critical part of adaptive thermogenesis in brown adipose tissue as it was found to be increased 
upon cold exposure. It was identified for its role in co-activating PPARγ by forming a 
heterodimer with RXR on the UCP-1 promoter region.34 This led to the interest in studying the 
interaction with PPARγ in promoting UCP-1 expression and thermogenesis. Further studies 
reveal many more capacities of PGC-1α, including mitochondria biogenesis and energy 
adaptation.62 PGC-1α is expressed at the highest levels in tissues that have high rates of oxidative 
metabolism including liver, kidney, and muscle tissues. In relation to thermogenesis in adipose 
tissue, in addition to its role in UCP-1 expression, PGC-1α induces expression of respiratory 
chain components that are encoded by mitochondrial DNA such as cytochrome oxidase subunits 
and ATP synthase subunits.8 A study that generated a PGC-1α- null brown fat cell line 
demonstrated that PGC-1α was required for mitochondrial biogenesis and increased 
thermogenesis in response to cAMP increases. However, it was not required for the phenotypic 
differentiation of BAT.63 
 
2.3.1 PGC-1α activation and modification 
 PGC-1α is activated through β-adrenergic activation via the cAMP dependent pathway. 
This pathway increases the transcriptional activity of PGC-1α by increasing the binding of 
CREB to the PGC-1α promoter. It was found in hepatic cells that when CREB was virally 
knocked down the induction of PGC-1α by a cAMP agonist was lost, leading to the conclusion 
that PGC-1α is a direct target of CREB.64 However, in brown adipocytes p38 MAPK can 
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increase transcription of PGC-1α and assists in regulation of the protein through 
phosphorylation.9, 10  
PGC-1α is activated by exercise in skeletal muscle where it contributes to energy 
adaptations.65, 66 It is also possible that with exercise an up regulation of PGC-1α in adipose is 
part of the associated metabolic improvements.67 This activation in adipose and muscle cells 
leads to increased respiration, which is considered positive for prevention of obesity and a 
potential therapeutic approach. However, p38MAPK phosphorylation of PGC-1α has been 
shown to be activated by cytokines and this activation is thought to be a driver of cachexia and 
muscle wasting that is clinically harmful in disease states such as cancer and trauma.68  
Posttranslational modifications are important for the regulation of PGC-1α as it has a 
half-life of 2.28 hours. Phosphorylation by p38MAPK can triple the half-life allowing for higher 
PGC-1α protein expression and increased activity.68 Deacetylation by SIRT1 is another 
modification that can increase PGC-1α activity to help modulate energy status of the cell and 
inhibition.11 The variety of modifications lends itself to the differential regulation and activity of 
PGC-1α in various tissue types. For example, in the liver deacetylation of PGC-1α increases the 
transcription of genes involved in gluconeogenesis but does not increase genes related to the 
electron transport chain as in adipose tissue. In adipose tissue PGC-1α increases UCP-1 but not 
aP2 which are both regulated by PPARγ, indicating greater specificity than coactivating 
PPARγ.69  
Several different pathways can also down regulate PGC-1α activity. RIP140 is a nuclear 
receptor corepressor that directly binds to PGC-1α and prevents its binding its downstream 
targets.70 When a chemical screen of transient receptor potential vanilloid 4 (TRPV4) agonists is 
done, there is an increase in PGC-1α expression, indicating the receptor can regulate expression. 
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In TRPV4 null mice, there was increased thermogenesis and protection from diet-induced 
obesity.71  
 
2.3.2 PGC-1α promotes mitochondrial biogenesis 
Mitochondrial biogenesis is the growth and division of mitochondrial that result in 
variation in number and size of cellular mitochondria.72 For its role in mitochondrial biogenesis, 
PGC-1α increases the gene expression of Nrf1 and Nrf2. These transcription factors work to 
promote a portion of mitochondria related genes including cytochrome c subunits by up 
regulating expression of Tfam. Tfam plays a critical role in its ability to translocate to the 
mitochondria in order to activate and coordinate mitochondrial DNA replication and 
transcription. Unlike increases in Nrf or Tfam alone, PGC-1α also plays a role in oxidative 
metabolism in skeletal muscle and cardiac muscle, indicating its importance in overall energy 
regulation.62 
This pathway is important for regulating the health of mitochondria. Dysfunction of 
mitochondria has been linked to aging, cancer, Alzheimer’s, and diabetes.72 Several studies have 
looked at muscle biopsies in humans to understand mitochondria content and insulin resistance. 
Morino etal looked at young lean individuals with insulin resistance that had parents with Type 2 
Diabetes. Insulin-mediated glucose update was 60% lower and mitochondrial density was 38% 
less than controls that had no insulin resistance or history of diabetes.73 In addition, two other 
studies found decreases in mitochondrial associated genes including PGC-1α, Nrf-1 and other 
downstream oxidative phosphorylation genes in diabetic subjects.74, 75 Further evidence of PGC-
1α in relation to diabetes is shown by a study that treated mice with the common anti-diabetic 
drug Metformin and found increases in muscle content of PGC-1α.76 All of this points to the 
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importance of PGC-1α and how its role in mitochondrial biogenesis and cellular metabolism can 
be beneficial in fighting against metabolic diseases.  
 
2.4 Overview of Naringenin 
2.4.1 Structure, dietary sources, and metabolism 
Naringenin has been found to function as an anti-inflammatory and antioxidant agent. It has 
been shown to be beneficial for hyperlipidemia, hypertension, hyperglycemia, diabetes, 
atherosclerosis, steatosis, inflammation as well as to be cardiac, and hepatic protective 
properties.77-82  
Plant based compounds such as polyphenols are actively researched to understand their 
beneficial properties in treating various diseases. Naringenin is a flavanone found in citrus fruits 
grapefruit, oranges and in much smaller amounts in tomatoes and mint.83 Naringin is the 
flavanone responsible for the bitter taste and when this compound is ingested it is converted by 
gut microbiota into the aglycone form; naringenin.84 When ingested in the aglycone form, 
naringenin is readily absorbed in the small intestine although the transporter has not been 
identified. Once absorbed, naringenin is then metabolized in the liver through methylation, 
sulfation and glucuronidation. The aglycone form in the blood is typically low after ingested at 
doses found in foods that contain naringenin. Even though the aglycone form is more efficiently 
absorbed in the small intestine, the glucuronides are found at the highest concentration in the 
blood. Polyphenols in general can be transported in circulation bound to albumin. However, it 
remains unclear where polyphenols accumulate within the body. Their excretion of polyphenols, 
especially flavanones, is through urine output but can also be excreted via the biliary route. 
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Additionally, absorption can vary related to individual differences in anatomy as well as dietary 
components present in the gastrointestinal tract with naringenin.83   
 
2.4.2 Plasma levels of naringenin in humans 
U.S. adults are estimated to consume about 189 mg/day of flavonoids with 14mg of them 
consisting of flavanones mostly from citrus fruit juice intake.85 Absorption and metabolism of 
naringenin varies between individuals and studies of plasma concentrations are ongoing. 
Estimation of intake is difficult due to the numerous variations in the content of foods, which is 
related to diverse growing conditions, storage, processing, and preparation.83  
In one study, participants consumed either orange juice or grapefruit juice that had 
concentrations of naringenin of 151 and 1283 µM respectively. The peak plasma concentrations 
of naringenin were 0.6 ± 0.4 µM from orange juice and 6.0 ± 5.4 µM from grapefruit juice.86 In a 
separate study, participants received 135 mg of naringenin, resulting in peak plasma 
concentrations ranging from 4.12 to 11.03 µM.87 These studies show that naringenin levels vary 
by source, dose, and the individual differences and a level of 10 µM is physiologically 
achievable. 
 
2.4.3 Assessment of the beneficial effects of naringenin: cell, animal, and human studies 
 Harmon and colleagues studied the effects of naringenin on proliferation of cultured 3T3-
L1 cells. Proliferation of 3T3-L1 cells was inhibited by naringenin in a time and dose dependent 
manner, Naringenin also caused an increased lactate dehydrogenase (LDH) release from the cells 
at 100ug/mL, indicative of cytotoxic effects of naringenin at this level.88 Therefore, it is 
important to use physiologically achievable doses.  
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  Naringenin has been shown to be an agonist of PPARα and PPARγ. Concentrations of 
naringenin used ranged from 0 to 240 µM.14  As noted above, PGC-1α is increased with cold 
stimulus increasing its ability to coactivate PPARγ at the UCP-1 promoter. NIH 3T3 cells were 
transfected with plasmids for PPARγ-Gal4 and Gal4- luciferase with naringenin for 24 hours. 
Naringenin dose dependently increased the luciferase activity, indicative of PPARγ activation.89 
 Rats fed a diet that contained 0.003, 0.006, or 0.012% naringenin for 6 weeks found 
significant reduction of triglycerides in adipose and liver tissue.79  
 Several animal studies using various mouse strains on diets containing naringenin 
reported reduced weight gain compared to the control diet. Ldlr-/- mice fed a high fat90 or high 
cholesterol78 diet that included 3% naringenin exhibited decreased adipocyte hypertrophy and 
resistance to diet induced weight gain than those that were not given naringenin. Three separate 
but similar studies utilized C57BL/6 mice that were fed a HFD77 or ovariectomized91 or that 
were ovariectomized and fed a HFD.92 Out of the groups fed naringenin, ovariectomized and 
high fat diet mice saw reduced weight gain while all three studies had decreased intra-abdominal 
adiposity. This shows promising effects that naringenin may be able to treat obesity.  
 Further demonstrating the beneficial potential of naringenin for obesity treatment, some 
human studies have been completed. Two studies had participants consume one-half of a 
grapefruit or the equivalent amount of grapefruit juice before meals. In one study, overweight 
adults followed this regime for 6 weeks. Participants had decreased waist circumference but no 
significant weight loss.93 Obese participants with metabolic syndrome that followed the same 
regime for 12 weeks in a randomized, double blinded study design, had a weight loss of 1.6kg 
and 1.5 kg (whole fruit vs. juice respectively).94 
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2.5 Overview of Indomethacin  
Indomethacin (INDO) was discovered as a non steroid anti-inflammatory drug (NSAID) 
in 1963 to treat joint swelling from rheumatoid arthritis.15  It works as a nonselective COX 
inhibitor for both COX1 and COX2. COX enzymes catalyze the rate limiting reaction that 
converts arachidonic acid and other omega-6 fatty acids to prostaglandins.95 Since then, it is used 
for treatment of various conditions related to inflammation. 
 An in vivo study in mice demonstrated that INDO treatment was protective against a high 
sucrose and high fat diet-induced obesity and decreased insulin sensitivity. However, INDO 
treated mice showed increased hepatic glucose output and glucose intolerance.96 It was reported 
that INDO promoted adipocyte differentiation in 3T3-L1 cells.97 In recent years, INDO is often 
used for brown preadipocyte differentiation. One study reported INDO activated PPARγ and 
PPARα.98 Interestingly, recent studies have reported that COX2, a rate-limiting enzyme in 
prostaglandin (PG) synthesis, is a downstream mediator of β-adrenergic signaling in WAT and is 
involved in induction of UCP1 expression in inguinal white adipocytes, but not in classic 
interscapular brown adipocytes.99, 100 Inhibition of COX by INDO suppressed UCP1 expression 
in the recruited brown adipocytes.99 This suggests that prostaglandin synthesis inhibited by 
INDO may not be required for classical brown adipogenesis but it may play a role in beige cell 
formation due to prostaglandins being a PPARγ ligand.101 Further research to better characterize 
INDO’s effects and mechanisms are warranted. 
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CHAPTER III 
NARINGENIN PROMOTES UP-REGULATION OF PGC-1ALPHA IN 
THERMOGENIC ACTIVATION OF 3T3-L1 
 
 
3.1. Introduction 
 
 Obesity continues to be a health problem in the US and is growing across the globe. 
Complications from the disease lead to increased health costs and decreases in quality of life for 
many.102 White and brown adipose tissues are responsible for energy storage and adaptive 
thermogenesis, respectively. Inducible thermogenesis is of interest to increase overall energy 
expenditure to fight obesity.3 Beige adipocytes are found in white adipose depots and are 
inducible to express UCP-1 for active thermogenesis.25 These cells can respond to similar stimuli 
as brown adipocytes such as cold, hormones, and some pharmacological agents to take on a 
brown-like phenotype, this process is called browning.103  
 Naringenin is a citrus flavanone that has been shown to have beneficial health effects. It 
is found at the highest levels in grapefruit.83 Positive effects on lipid metabolism, inflammation 
and resistance to diet-induced weight gain by naringenin have been demonstrated.82 In mice, it 
has been shown that naringenin is protective against increased weight gain induced by a high fat 
or high cholesterol diet and in a similar study the levels of triglycerides were improved by 
naringenin.78, 90, 92 In vitro naringenin has been shown to be a PPARγ agonist.14 PPARγ can bind 
to the PPRE site on the UCP-1 promoter and is coactivated by PGC-1α.28 Pharmacological 
PPARγ agonist rosiglitazone promotes browning in WAT cultures, leading to up regulation of 
UCP-1 and thermogenesis.55, 104 However, it is unclear whether naringenin can promote the 
browning effect and what cellular mechanisms drive its beneficial effects.  
 As a coactivator for PPARγ and other transcription factors, PGC-1α is important in 
brown adipose tissue function and plays an important role in UCP-1 transcription, mitochondrial 
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biogenesis and oxidative metabolism.62 We aim to study whether naringenin can increase 
browning and up regulate PGC-1α expression. We utilized 3T3-L1 adipocytes differentiated in 
the presence of varying physiologically achievable doses of naringenin and then stimulated cells 
with isoproterenol, a β-adrenergic receptor agonist. 
  
3.2. Materials and Methods 
3.2.1 Reagents 
Murine 3T3-L1 cells were obtained from ATCC (Manassas, VA). Naringenin, dimethyl 
sulfoxide (DMSO), 3-Isobutyl-L-methylxanthine, dexamethasone, insulin, isoproterenol (ISO), 
and rosiglitazone (Rosi) were from Sigma Aldrich (St. Louis, MO). Calf serum (CS) was 
purchased from Hyclone (Logan, UT) and fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals (Flowery Branch, GA). UCP-1 antibody was purchased from Sigma Aldrich (St. 
Louis, MO), PGC-1α from Millipore (Temecula, CA), ERK1/2 antibody, and horseradish 
peroxidase-conjugated goat anti-rabbit were from Cell Signaling Technology (Danvers, MA).  
3.2.2 Cell culture and treatment 
Murine 3T3-L1 cells were cultured in DMEM supplemented with 10% CS and 1% 
penicillin and streptomycin at 37°C humidified atmosphere of 5% CO2 until they reached 
confluence [designated as day 0 (D0)]. The cells were differentiated in DMEM containing 10% 
FBS, 1 µM dexamethasone, 0.5 mM, 5µM 3-isobutyl-1-methylxanthine (IBMX) and 10 µg/mL 
insulin for 3 days (D0-D3), followed by treatment with 10 µg/mL insulin in DMEM containing 
10% FBS for an additional 2 days (D3-D5). The cells were then maintained in DMEM 
containing 10% FBS until fully differentiated at day 7 (D7). Naringenin doses 5, 10, 20 µM at 
start of differentiation and replaced with each media change. Rosi (1 µM) was used as a positive 
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control. On D7, the cells were stimulated with Isoproterenol (ISO, 1 µM) or the vehicle control 
for 6 h for RNA or 24 h for protein samples. 
 
3.2.3 Western blot analysis 
Total cell lysates were prepared using 1X RIPA buffer (Cell Signaling, Danvers, MA) 
and protein concentration were determined by the BCA assay kit (Thermo Scientific, Waltham, 
MA). Total cell lysates were subjected to 10% SDS-PAGE and transferred to polyvinylidene 
difluoride membrane (Bio-Rad, Hercules, CA). The membrane was blocked in 20 mM Tris Base, 
137 mM NaCl, and 0.1% Tween 20 (pH 7.4) containing 5% nonfat milk. The membrane was 
immunoblotted with primary antibodies at 4°C overnight followed by secondary antibody 
conjugated with horseradish peroxidase for 1 h. Proteins were visualized using ECL western blot 
detection reagents (Pierce, Rockford, IL). Pixel intensities of immunoreactive bands were 
quantified using ChemiDocXRS+ imaging system with ImageLab software (Bio-Rad). 
3.2.4 RNA, DNA preparation and semi-quantitative real-time PCR analysis 
Total RNA was prepared using TRI reagent (Molecular Research Center, Cincinnati, OH) 
according to the manufacturer’s instructions. Total RNA abundance was quantified using 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse 
transcription was carried out using High capacity cDNA Reverse Transcription kit (Thermo 
Scientific, Pittsburgh, PA) according to the manufacturer’s instructions. mRNA expression of 
target genes and the housekeeping gene 36B4 was measured semi-quantitatively using Power Up 
SYBR master mix (Applied Biosystems, Austin TX). PCR reactions were run in a 96-well 
format using an ABI 7300HT instrument. Cycle conditions were 50°C 2 min, 95°C 10 min and 
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then 40 cycles of 95°C for 15 s, 60°C for 1 min. Relative gene expression was calculated using 
the 2-ΔΔCt method, which normalizes with house keeping gene 36B4. 
DNA was prepared using TRI reagent (Molecular Research Center, Cincinnati, OH) 
according to the manufacturer’s instructions and total DNA concentration was quantified using 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). COX II as 
well as 18S control gene were measured semi-quantitatively using Power Up SYBR master mix 
(Applied Biosystems, Austin TX). PCR reactions were run in a 96-well format using an ABI 
7300HT instrument. Cycle conditions were 50°C 2 min, 95°C 10 min and then 40 cycles of 95°C 
for 15 s, 60°C for 1 min. Relative DNA content  was calculated using the 2-ΔΔCt method, which 
normalizes with 18s ribosomal DNA. 
3.2.5 Statistical analysis 
 Data for mRNA and DNA experiments are presented as mean ± SEM. Measurements 
were performed in triplicates. Statistical analysis was performed using SigmaPlot 13.0 (Systat 
Software). One-way ANOVA followed by multiple comparisons test (Student-Newman-Keuls 
method) was performed to determine the differences of group mean between the treatment 
groups. The level of significance was set at P<0.05. 
 
 
3.3 Results 
 
3.3.1 Naringenin dose-dependently increases PGC-1α mRNA in isoproterenol stimulated 
3T3-L1 adipocytes. 
To demonstrate the effects of naringenin on white adipocytes, 3T3-L1 preadipocytes 
were differentiated in the presence or absence of naringenin (5, 10, 20 µM) for 7 days and then 
stimulated with isoproterenol (ISO) or the vehicle control for 6 hours to induce thermogenic 
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activation. Rosiglitazone was included as a positive control. At basal (non-ISO stimulated) 
conditions, thermogenic markers PGC-1α and UCP-1 were not increased by naringenin (Fig. 
1A). However, under ISO stimulation naringenin dose-dependently increased UCP-1 and PGC-
1α mRNA (p<0.05) (Fig. 1B). PPARγ showed no significant differences among naringenin 
doses, suggesting no differences in differentiation among treatments. Mitochondrial marker Nrf-
1 and Tfam showed modest increases that were not significant under basal conditions. Under 
ISO stimulation, Nrf-1 was significantly increased by naringenin at 10 µM. SIRT1 had no 
significant differences for naringenin treatments under basal or ISO stimulated conditions.  
Beige markers Tmem26 and CD137 showed no significant differences among naringenin 
treatments under basal conditions. However, Tmem26 was significantly decreased by naringenin 
under ISO stimulated conditions. No differences were shown in CD137 mRNA levels by 
naringenin. Brown adipocyte marker Meox-2 was significantly increased under basal conditions 
by naringenin at 5 and 10 µM; however, Meox-2 was significantly decreased when cells were 
stimulated by ISO with the exception of the positive control Rosi, which was increased by ISO 
(Fig. 1B). 
 
3.3.2 Naringenin dose-dependently enhances UCP-1 and PGC-1α protein expression in 
ISO-stimulated 3T3-L1 adipocytes.  
 To determine if the increases in PGC-1α and UCP-1 mRNA lead to increases in protein 
expression we collected protein samples in a parallel experiment. 3T3-L1 cells were 
differentiated for 7 days with naringenin (5, 10, 20 µM) and then stimulated with or without ISO 
for 24 hours. Dose-dependent increases were seen under both basal and ISO stimulated 
conditions (Fig 2).  
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3.3.3 Naringenin increases the ratio of mitochondrial COXII/ nuclear 18S DNA in 3T3-L1 
adipocytes. 
 To provide further evidence for naringenin’s effects on PGC-1α, we compared 
mitochondrial DNA to the nuclear DNA by measuring a ratio of COX II (cytochrome c oxidase 
subunit II, a mitochondrial DNA coded gene) over 18S, (a nuclear DNA coded gene). At basal 
conditions, naringenin dose-dependently increased the ratio of COXII/18S and reached 
significance when used at 20 µM (p<0.05). As expected, the positive control Rosi significantly 
increased COXII/18S (p<0.01). (Fig. 3). This is indicative of increased mitochondrial DNA copy 
number and therefore increased mitochondrial biogenesis.  
 
3.4 Discussion and Conclusions 
 Targeting beige adipocytes to increase thermogenesis and energy expenditure is a novel 
approach for obesity treatment and prevention. 25, 105 Naringenin, a citrus flavanone, has been 
previously shown to have beneficial effects on lipid metabolism and inflammation. We report 
that naringenin dose-dependently enhanced ISO-stimulated UCP-1 and PGC-1α mRNA 
expression. Consistently, naringenin dose-dependently increases UCP-1 and PGC-1α protein 
expression under both basal (non-ISO stimulated) and ISO stimulated conditions. Furthermore, 
at basal condition naringenin at 20 µM significantly increased the ratio of COXII/18S. Our study 
demonstrates that in addition to increased UCP-1 expression, naringenin promotes up regulation 
of PGC-1α and mitochondrial biogenesis in thermogenic activation of 3T3-L1 adipocytes.  
 To our knowledge we are the first to report that naringenin at a physiologically 
achievable dose, can enhance PGC-1α expression and increased mitochondrial DNA to nuclear 
DNA ratio in 3T3-L1 cells. It is conceivable that increased UCP-1expression under the ISO-
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stimulated condition by naringenin, may be due to naringenin’s ability to up-regulate PGC-1α 
expression as it is known that PGC-1α coactivates PPARγ on the UCP-1 promoter to increase 
UCP-1 transcription. Consistently, we show naringenin dose-dependently increased 
mitochondrial DNA as evidenced by the increased ratio of COXII/18S. Taken together, we 
demonstrate that naringenin promotes up regulation of PGC-1α, leading to increased 
mitochondrial biogenesis. These results suggest that naringenin may be beneficial for chronic 
conditions in which mitochondrial dysfunction is implicated, such as diabetes, endocrine 
dysfunction and Alzheimer’s diseases.106, 107  
We utilized Rosi, a known browning agent, as a positive control. We show that in 
addition to increased UCP-1 and PGC-1α expression, Rosi also significantly increased beige 
marker CD137 (under ISO-stimulated condition) and a novel brown marker Meox-2 (under both 
basal and ISO-stimulated conditions). Interestingly, Rosi seemed to suppress rather than to 
increase Tmem26 mRNA, another known beige marker. Wu etal found that Tmem26 was 
increased in beige culture except for one human sample, which showed a decrease in Tmem26.25 
However, our finding that Tmem26 was decreased by Rosi treatment was consistent with the 
findings by deJong and Garcia.42, 43 While our data does not definitively show a beige phenotype 
by naringenin treatment, our finding of Tmem26 expression is consistent with other studies in 
thermogenic activated cells. This discrepancy suggests the need for a better understanding of 
beige cell origin and beige marker genes. 
In conclusion, we have shown that naringenin dose-dependently increases PGC-1α 
expression and consequently mitochondrial biogenesis in ISO-stimulated 3T3-L1 adipocytes. 
Since PGC-1α is a major regulator of mitochondrial biogenesis and oxidative metabolism, future 
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studies of naringenin on diabetes, endocrine dysfunction and other chronic diseases in which 
mitochondrial dysfunction is implicated are warranted. 
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CHAPTER IV 
INDOMETHACIN INDUCES BROWN ADIPOCYTE DIFFERENTIATION  
 
4.1. Introduction  
 
 As obesity continues to persist in the US population and across the world, new 
interventions are needed to treat those currently impacted and prevent further spread of the 
disease. While lifestyle changes including diet, physical activity and behavior change can be 
used for treatment, they take a longer duration to implement and show slower improvements. 
Pharmacological agents that target adipose tissue have been used, but have dwindled due to 
harmful side effects, such as congestive heart failure by Rosiglitazone.108 Other weight loss 
agents, such as the lipase inhibitor Orlistat, lead to undesirable malabsorption of lipids and lipid 
soluble vitamins.109 Invasive interventions such as bariatric surgery are used but require major 
surgery, which can lead to post-surgery complications.  
 Indomethacin (INDO) is an FDA approved NSAID that is currently used to treat fever, 
pain and swelling related to inflammation. It acts as a non-selective COX inhibitor to inhibit 
prostaglandin synthesis.95 Early research demonstrated that INDO activates PPARγ, a ligand-
activated transcription factor playing a critical role in adipogenesis and promoted white 
adipocyte differentiation of a mesenchymal stem cell line C3H10T1/2.110 Moreover, 
supplementation of INDO (HF/HS+INDO) prevented high fat/high sucrose-induced (HF/HS) 
weight gain, white fat increases and insulin resistance in obesity prone C57BL/6J mice.16 White 
and brown differentiation share general characteristics and signaling pathways; therefore, we aim 
to study INDO on brown adipocyte differentiation. We modified our brown differentiation 
protocol to include insulin and T3 but without the induction by dexamethasone and IBMX to 
decrease the basal differentiation and more clearly delineate INDO’s effects. 
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4.2 Materials and Methods 
4.2.1 Reagents 
Indomethacin, Insulin, T3, rosiglitazone (Rosi), and dimethyl sulfoxide (DMSO) are from 
Sigma Aldrich (St. Louis, MO). Primary antibodies for UCP-1 were from Sigma Aldrich (St. 
Louis, MO), PGC-1α from Millipore (Temecula, CA), ERK1/2 and horseradish peroxidase-
conjugated goat anti-rabbit was from Cell Signaling Technology (Danvers, MA).  
4.2.2 Cell culture and treatment 
The murine brown fat cell line is a gift from Dr. Johannes Klein (University of Lubeck, Lubeck, 
Germany), who has generated the cell line from interscapular brown fat of newborn C57BL/6 
mice (Klein, 2002). Brown fat cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 20% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA) 
at 37 °C humidified atmosphere of 5 % CO2 in air, until they reached 100% confluence 
(designated as day 0). The cells were then induced to differentiate by treatment with 
differentiation media containing DMEM supplemented with 20% FBS, 1 nM T3, and 20 nM 
insulin every 2 days until day 4. To study the effects of INDO promoting differentiation in 
brown adipocytes, INDO (2, 5, 10, 20, 50 µM) or the vehicle control DMSO was added at D0 
and replaced with each change of the media during the differentiation process. 
4.2.3 Western blot analysis 
Total cell lysates were prepared using 1X lysis buffer (Cell Signaling, Danvers, MA) and 
protein concentration were determined by the BCA assay kit (Thermo Scientific, Waltham, MA). 
Total cell lysates were subjected to 10% SDS-PAGE and transferred to polyvinylidene difluoride 
membrane (Bio-Rad, Hercules, CA). The membrane was blocked in 20 mM Tris Base, 137 mM 
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NaCl, and 0.1% Tween 20 (pH 7.4) containing 5% nonfat milk. The membrane was 
immunoblotted with primary antibodies at 4°C overnight followed by secondary antibody 
conjugated with horseradish peroxidase for 1 h. Proteins were visualized using ECL western blot 
detection reagent (Pierce, Rockford, IL). Pixel intensities of immunoreactive bands were 
quantified using ChemiDocXRS+ imaging system with ImageLab software (Bio-Rad). 
4.2.4 RNA, DNA preparation and semi-quantitative real-time PCR analysis 
Total RNA was isolated using TRI reagent (Molecular Research Center, Cincinnati, OH) 
according to the manufacturer’s instructions. Total RNA was quantified using NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse transcription was 
carried out using High capacity cDNA Reverse Transcription kit (Thermo Scientific, Pittsburgh, 
PA) according to the manufacturer’s instructions. mRNA expression of target genes and the 
housekeeping gene 36B4 was measured quantitatively using Power Up SYBR master mix 
(Applied Biosystems, Austin TX). PCR reactions were run in a 96-well format using an ABI 
7300HT instrument. Cycle conditions were 50°C 2 min, 95°C 10 min and then 40 cycles of 95°C 
for 15 s, 60°C for 1 min. Relative gene expression was calculated using the 2-ΔΔCt method, which 
normalized by house keeping gene 36B4. 
DNA was prepared using TRI reagent according to the manufacturer’s instructions and 
total DNA concentration was quantified using NanoDrop ND-1000 spectrophotometer. COX II 
as well as 18S control gene were measured quantitatively using Power Up SYBR master mix. 
PCR reactions were run in a 96-well format using an ABI 7300HT instrument. Cycle conditions 
were 50°C 2 min, 95°C 10 min and then 40 cycles of 95°C for 15 s, 60°C for 1 min. Relative 
DNA content was calculated using the 2-ΔΔCt method, which normalized by 18S DNA. 
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4.2.5 Reporter gene assays 
Brown preadipocytes seeded in 48-well plates were transiently transfected with PPRE-
Luc reporters (PPRE X3-TK-luc was a gift from Bruce Spiegelman, Addgene plasmid # 1015) 
and β-galactosidase expression plasmid with Lipofectamine 2000 transfection reagent and Plus 
reagent (Thermo Fisher Scientific, Carlsbad, CA). Twenty-four hours post transfection the cells 
were then treated with INDO or the vehicle control DMSO for 18 h. The cell lysate was prepared 
and reporter luciferase and β-galactosidase activities were measured with GloMax Luminometer 
(Promega, Madison, WI). Relative luciferase activities were normalized by β-galactosidase 
activities. 
4.2.6 Statistical analysis 
Data for ORO, mRNA, DNA and reporter experiments are presented as mean ± SEM. 
Measurements were performed in triplicates. Statistical analysis was performed using SigmaPlot 
13.0 (Systat Software). One-way ANOVA followed by multiple comparisons test (Student-
Newman-Keuls method) was performed to determine the differences of group mean between the 
treatment groups. The level of significance was set at P<0.05. 
 
4.3. Results  
 
4.3.1 Indomethacin increases brown adipocytes differentiation as measured by Oil Red O 
stained cell morphology and absorbance. 
 After 6 days of differentiation, brown preadipocytes show morphological changes that 
include multilocular lipid formation, consistent with mature brown adipocytes. INDO dose-
dependently increased lipid accumulation with significant increases at 20 and 50 µM (p<0.05) 
(Fig. 4), demonstrating its positive effects on brown adipocyte differentiation.  
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4.3.2 Indomethacin dose-dependently increases mRNA and protein expression of PGC-1α 
and UCP-1 in brown adipocytes.  
 To investigate the effect of INDO on brown adipocyte differentiation, brown 
preadipocytes were differentiated as described in the materials and methods section. INDO dose-
dependently increased PPARγ mRNA and reached statistical significance from 5 to 50 µM 
(p<0.05) (Fig. 5). Moreover, INDO dose-dependently increased PGC-1α mRNA (p<0.05) (Fig. 
5). Treatment with INDO at a dose of 10 µM or higher resulted in a significant increase in UCP-
1 mRNA levels (p<0.05). Additionally, naringenin dose-dependently increased brown marker 
PRDM16 (p<0.05). Mitochondrial markers Tfam, and Nrf-1 were not significantly increased by 
INDO (Fig. 5). Furthermore, we show that INDO increased protein expression of PGC-1α and 
UCP-1 (Fig. 6), consistent with the changes in mRNA expression. 
 
4.3.3 Indomethacin increases mitochondrial DNA in brown adipocytes.  
 To provide more evidence for indomethacin’s induction of brown adipocyte 
differentiation, we isolated mitochondrial DNA and measured the ratio of mitochondrial COX II 
(cytochrome c oxidase subunit II) over 18S nuclear DNA. Significant increases in mitochondrial 
DNA/nuclear DNA were seen when cells were treated with INDO at a dose of 20 µM or 50µM 
(p<0.001) (Fig. 7). 
 
4.3.4 Indomethacin activates PPRE reporter in brown preadipocytes. 
 INDO has previously been shown to bind and activate PPARγ. To explore the molecular 
mechanisms by which INDO promoted brown adipocyte differentiation, the PPAR responsive 
reporter gene assay (PPRE-Luc) was performed. INDO significantly increased PPAR responsive 
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luciferase reporter activity at 20 µM in brown preadipocytes, suggesting an increase in PPARγ 
activity (p<0.05) (Fig. 8). Rosiglitazone, a known PPARγ ligand, was used as a positive control. 
 
4.4. Discussion and Conclusions 
 
Increasing functional brown adipose activity has become a novel target for obesity 
treatment and prevention. We show here that indomethacin, a commonly used cyclooxygenase 
inhibitor dose-dependently promotes brown adipocyte differentiation, as revealed by increased 
lipid accumulation, increased expression of brown marker genes and increased mitochondrial 
biogenesis. We further demonstrate that INDO dose-dependently activates PPAR responsive 
reporter activities, consistent with a previous reports.98 These results suggest that INDO 
promotes brown adipocyte differentiation possibly through activation of PPARγ. More research 
is needed to determine the role of other transcription factors that bind to the PPRE site such as 
PPARα. 
To our knowledge, this is the first time to demonstrate that INDO is capable of inducing 
brown adipocyte differentiation in the absence of dexamethasone and IBMX. PPARγ signaling is 
considered to be critical for both white and brown adipocyte differentiation.31 A synthetic 
PPARγ agonist rosiglitazone has been demonstrated to be a “browning” agent inducing 
formation of brown-like adipocytes in certain white fat depot.44 Similarly, the finding that UCP-1 
mRNA in inguinal WAT was higher in INDO treated (HF/HS+INDO) mice compared to the 
controls (HF/HS) suggests that INDO may promote browning in vivo. It was reported that INDO 
increased UCP-1 expression in the interscapular brown adipose tissue (iBAT) in INDO treated 
mice (HF/HS+INDO) compared to the controls (HF/HS); however, it was not significant, 
possibly due to the higher stimulation of UCP-1 mRNA by high fat/high sucrose diet.16 It has 
been suggested that the ability of PPARγ agonists to induce brown differentiation and browning 
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are related to their abilities to induce expression of PGC-1α.55, 111 We have shown that INDO 
dose-dependently increased both mRNA and protein expression of PGC-1α. Further studies are 
needed to define the role of PGC-1α in INDO’s effects on brown adipocyte differentiation.  
In conclusion, we demonstrate for the first time that INDO, a commonly used NSAID 
and COX inhibitor, dose-dependently promotes brown adipocyte differentiation in the absence of 
dexamethasone and IBMX. In light of the effects of INDO on white adipocyte differentiation and 
other detrimental effects on liver, pancreatic β-cells, and gastric integrity, targeted delivery of 
INDO to brown fat depot during development may be further explored to increase brown adipose 
tissue mass/function for obesity treatment and prevention in the future.  
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Figure 1. Effect of naringenin on mRNA expression of thermogenic, beige and brown 
markers with and without isoproterenol stimulation.  
3T3-L1 preadipocytes were induced to differentiate in the presence or absence of 
increasing doses of naringenin (5, 10, 20 µM) for 7 days. On day 7, matured 3T3-L1 
adipocytes were treated with isoproterenol (ISO) for 6 hours or the vehicle control 
DMSO. Target gene expression was normalized by 36B4 and relative fold changes are 
compared to the DMSO control. (A) mRNA expression without ISO stimulation. (B) 
mRNA expression with ISO stimulation. Rosiglitazone was used as a positive control. 
Data= mean± SEM (n=3). ***, p<0.001; **, p<0.01;*, p<0.05 compared to the DMSO 
group. 
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Figure 1. Continued 
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Figure 1. Continued 
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Figure 2. Effect of naringenin on PGC-1α and UCP-1 protein expression. 
3T3-L1 cells were differentiated with increasing doses of naringenin (5, 10, 20 µM) until day 
7 when they were treated with isoproterenol for 24 hours. Total cell lysates were prepared and 
analyzed by western blot. Densitometry was determined using ChemiDocXRS+ imaging 
system with ImageLab software. ERK1/2 was utilized as a loading control.  
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Figure 3. Naringenin increases the ratio of mitochondrial DNA marker CoxII over 18S 
DNA.  
3T3-L1 cells were differentiated for 7 days in the presence or absence of Naringenin (5, 10, 
20 µM). Total DNA was extracted and mitochondrial DNA content was quantified by the 
ratio of CoxII to 18S DNA. Relative changes are expressed as fold changes and compared to 
the DMSO control. Data= mean± SEM (n=3). **, ***, p<0.01 and p<0.001, respectively, 
compared to the DMSO group. 
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Figure 4. Indomethacin dose-dependently induces brown adipocyte differentiation.  
(A) Oil red O stained cell morphology at day 6 (B) Lipid accumulation measured by oil red 
O absorbance. Negative control cells were set at fold 1. Data= mean± SEM (n=3). Brown 
preadipocytes were differentiated in the presence or absence of increasing doses of INDO (2, 
5, 10, 20, 50 µM) until day 6. ***, p<0.001 compared to the DMSO group.  
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Figure 5. Indomethacin dose-dependently increases mRNA expression of brown 
adipocyte marker genes.  
Brown preadipocytes were induced to differentiation in the presence or absence of 
increasing doses of INDO (2, 5, 10, 20, 50 µM) for 4 days. Target gene expression was 
normalized by 36B4 and relative fold changes are compared to DMSO control. Data= 
mean± SEM (n=3). ***, p<0.001; **, p<0.01;*, p<0.05 compared to the DMSO group. 
  49 
 
Figure 6. Indomethacin dose-dependently increases PGC-1α and UCP-1 protein 
expression.  
3T3-L1 cells were differentiated in the presence or absence of increasing doses of INDO (2, 5, 
10, 20, 50 µM) until day 4. Total cell lysates were prepared and analyzed using western blot 
(A). (B) Densitometry was determined using ChemiDocXRS+ imaging system with 
ImageLab software. ERK1/2 was utilized as a loading control.  
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Figure 7. Indomethacin dose-dependently increases ratio of mitochondrial DNA 
marker CoxII over18s DNA. 
Brown preadipocytes were differentiated for 4 days in the presence or absence of INDO (2, 
5, 10, 20, 50 µM). Total DNA was extracted. Mitochondrial DNA content was quantified by 
the ratio of COXII to 18s ribosomal DNA. Relative changes are expressed as fold changes 
and compared to the DMSO control. Data= mean± SEM (n=3).	 ***, p<0.001 compared to 
the DMSO group. 
Figure 8. Indomethacin activates PPRE-Luc luciferase activity in brown preadipocytes. 
Brown preadipocytes were transfected with PPRE-Luc plasmid and treated for 18 hours with 
or without INDO (2, 5, 10, 20, 50 µM). Luciferase activity was measured and normalized by 
β-galactosidase activity. Relative changes are expressed as fold changes and compared to the 
negative control (-). Data= mean± SEM (n=3).	 *, p<0.05 compared to the DMSO group. 
  51 
VITA 
 
Jamie Ann Kearns was born to Sheila Simpson Kearns and Warren Kearns in Torrington, 
Wyoming where she completed high school. She then attended the University of Wyoming 
graduating in 2014 earning her Bachelor of Science in Family Consumer Sciences with a 
concentration in Dietetics. While enrolled she worked as a nutrition aide for UW Dining services 
and participated in animal research. Upon graduation, she moved to Knoxville, Tennessee to 
complete a combined Masters/Dietetic Intern program at the University of Tennessee, Knoxville. 
During the program, she completed her thesis research under Dr. Ling Zhao for the Cellular and 
Molecular Nutrition concentration. She completed the dietetic internship with a clinical focus at 
several area hospitals. While at UTK she was also employed as a graduate assistant in the small 
animal facility. She defended her thesis on November 3rd, 2016. She intends to sit for the 
Commission of Dietetic Registration exam and has already accepted a position as a clinical 
dietitian at Rapid City Regional Hospital in South Dakota. 
 
 
